The development of a fully autonomous artificial pancreas system (APS) to independently regulate the glucose levels of a patient with Type 1 diabetes has been a long-standing goal of diabetes research. A significant barrier to progress is the difficulty of testing new control algorithms and safety features, since clinical trials are time- and resource-intensive. To facilitate ease of validation, we propose an open-source APS testbed by integrating APS controllers with two state-of-the-art glucose simulators and a novel fault injection engine. The testbed is able to reproduce the blood glucose trajectories of real patients from a clinical trial conducted over six months. We evaluate the performance of two closed-loop control algorithms (OpenAPS and Basal Bolus) using the testbed and find that more advanced control algorithms are able to keep blood glucose in a safe region 93.49% and 79.46% of the time on average, compared with 66.18% of the time for the clinical trial. The fault injection engine simulates the real recalls and adverse events reported to the U.S. Food and Drug Administration (FDA) and demonstrates the resilience of the controller in hazardous conditions. We used the testbed to generate 2.5 years of synthetic data representing 20 different patient profiles with realistic adverse event scenarios, which would have been expensive and risky to collect in a clinical trial. The proposed testbed is a valid tool that can be used by the research community to demonstrate the effectiveness of different control algorithms and safety features for APS.
翻译:发展完全自主的人工胰腺系统(APS)以独立调节患有1型糖尿病的病人的葡萄糖含量一直是糖尿病研究的长期目标。进展的一个重大障碍是难以测试新的控制算法和安全特征,因为临床试验是时间和资源密集型的。为了便于验证,我们提议开发一个开放源码的APS测试台,将APS控制器与两个最先进的葡萄糖模拟器和一个新的错误注射引擎结合起来。测试台能够复制6个月临床试验中真实病人的血糖糖糖糖糖色轨迹。我们利用测试台评估了两个闭路控制算法(OpenAPS和Basal Bolus)的性能,发现更先进的控制算法能够将血糖保持在安全区域93.49%和79.46%的平均时间进行测试,而临床试验的时间为66.18%。错误注射引擎可以模拟向U.S.S.使用的风险测试室社区报告的实际回顾和不利事件。我们使用了一个风险测试室,一个用于25年的食品和药物管理局的测试模型将展示一个风险测试模型。我们用了20年的数据。我们用过了一个用于一个危险的实验室。